Comparison of Compliance of Different Iron Chelators Including Original and Bioequivalents of Deferasirox

Basit Öğe Kaydı
dc.contributor.authorGüzelküçük, Zeliha
dc.contributor.authorAksu, Tekin
dc.contributor.authorUnal, Şule
dc.contributor.authorÖzbek, Namık Yaşar
dc.contributor.authorSöker, Murat
dc.contributor.authorYaralı, Neşe
dc.contributor.authorCoşkun, Çağrı
dc.date.accessioned2024-04-24T19:11:51Z
dc.date.available2024-04-24T19:11:51Z
dc.date.issued2020
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: The current iron chelation therapy regimens include deferoxamine, deferiprone, and deferasirox in transfusion-dependent patients. Compliance with iron-chelating therapy is one of the significant determinants of mortality and morbidities related to iron overload in chronically transfused patients. This survey aims to compare the compliance to treatment with deferoxamine, deferiprone, and deferasirox and the taste of oral formulations in three hematology centers from Turkey. Moreover, the bioequivalent (generic) formulations of dispersible deferasirox tablets were compared with the original formulation in terms of taste and treatment compliance. Material and Methods: A written questionnaire with a list of pre-set questions was applied to measure patient-reported outcomes to a total of 85 patients, where 77 had beta-thalassemia major, 7 had beta-thalassemia intermedia, and 1 had sickle cell anemia diagnoses. Results: The patients’ median age at enrollment was 15 years (range 7 – 42). The compliance was below 50% in 8 (18.6%), 4 (16%), and 5 (6.7%) in patients receiving deferoxamine, deferiprone, and deferasirox, respectively. Additionally the compliance was below 80% in 16 (37.2%), 9 (36%), and 17 (22.6%) in patients receiving deferoxamine, deferiprone, and deferasirox, respectively. It was found that 39 (47%) patients had compliance problems due to the dispersible deferasirox tablet formulations’ taste, except combination therapies. There was no difference between the currently used oral chelators in terms of taste and treatment compliance. Conclusion: This study draws attention to compliance problems in patients with iron-loading anemias, partly due to the unpleasant taste of deferasirox. Improving patient satisfaction and compliance with iron-chelator therapy may reduce complications of iron overload.en_US
dc.identifier.endpage43en_US
dc.identifier.issn2147-9488
dc.identifier.issue3en_US
dc.identifier.startpage38en_US
dc.identifier.trdizinid486460
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/486460
dc.identifier.urihttps://hdl.handle.net/11468/28225
dc.identifier.volume51en_US
dc.indekslendigikaynakTR-Dizin
dc.language.isoenen_US
dc.relation.ispartofActa Medica
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleComparison of Compliance of Different Iron Chelators Including Original and Bioequivalents of Deferasiroxen_US
dc.titleComparison of Compliance of Different Iron Chelators Including Original and Bioequivalents of Deferasirox
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu